Targeting ALK-rearranged non-small-cell lung cancer: an update

Future Oncol. 2017 Jun;13(14):1213-1217. doi: 10.2217/fon-2017-0127. Epub 2017 Jun 7.
No abstract available

Keywords: anaplastic lymphoma kinase-rearrangement; new-generation anaplastic lymphoma kinase tyrosine kinase inhibitors; non-small-cell lung cancer.

Publication types

  • Editorial

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Clinical Trials as Topic
  • Disease-Free Survival
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Gene Rearrangement / genetics
  • Humans
  • Molecular Targeted Therapy*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Sulfones / therapeutic use

Substances

  • Protein Kinase Inhibitors
  • Pyrimidines
  • Sulfones
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • EGFR protein, human
  • ErbB Receptors
  • Receptor Protein-Tyrosine Kinases
  • ceritinib